News & Events about Poseida Therapeutics Inc.
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition PR...
Ticker Report
6 months ago
Poseida Therapeutics, Inc. (NASDAQ:PSTX Get Rating) Analysts at William Blair decreased their FY2023 EPS estimates for Poseida Therapeutics in a research note issued on Thursday, November 10th. William Blair analyst R. Prasad now expects that the company will post earnings of $0.89 ...
Poseida Therapeutics, Inc. (NASDAQ:PSTX Get Rating) William Blair dropped their FY2023 earnings per share estimates for shares of Poseida Therapeutics in a research report issued to clients and investors on Thursday, November 10th. William Blair analyst R. Prasad now forecasts that the company will ...
Poseida Therapeutics to Present at Two Upcoming Investor Conferences Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 8, 2022 SAN DIEGO, Nov. 8, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company...